Topical calcineurin inhibitors in systemic lupus erythematosus

References

• GillianJNSontheimerRDDistinctive cutaneous subsets in the spectrum of lupus erythematosusJ Am Acad Dermatol198144714757229150
   PubMed Web of Science ®Google Scholar
• KuhnARuzickaTClassification of cutaneous lupus erythematosusKuhnALehmannPRuzickaTCutaneous lupus erythematosusHeidelberg, GermanySpringer2005
   Google Scholar
• TingWWSontheimerRDLocal therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerationsLupus20011017118411315348
   PubMed Web of Science ®Google Scholar
• SárdyMRuzickaTKuhnATopical calcineurin inhibitors in cutaneous lupus erythematosusArch Dermatol Res2009301939818797893
   PubMed Web of Science ®Google Scholar
• HomeyBAssmannTVohrHWTopical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responsesJ Immunol1998160533153409605132
   PubMed Web of Science ®Google Scholar
• GisondiPEllisCNGirolomoniGPimecrolimus in dermatology: Atopic dermatitis and beyondInt J Clin Pract20055996997416033622
   PubMed Web of Science ®Google Scholar
• MarslandAMGriffithsCEThe macrolide immunosuppressants in dermatology: Mechanisms of actionEur J Dermatol20021261862212459545
   PubMed Web of Science ®Google Scholar
• GrassbergerMSteinhoffMSchneiderDLugerTAPimecrolimus – an anti-inflammatory drug targeting the skinExp Dermatol20041372173015560755
   PubMed Web of Science ®Google Scholar
• MeindlSVaculikCMeingassnerJGDifferential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and miceJ Invest Dermatol20091292184219219295616
   PubMed Web of Science ®Google Scholar
• BillichAAschauerHAszodiAStuetzAPercutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimusInt J Pharm2004269293514698574
   PubMed Web of Science ®Google Scholar
• WeissHMFresneauMMoeniusTStuetzABillichABinding of pimecrolimus and tacrolimus to skin and plasma proteins: Implications for systemic exposure after topical applicationDrug Metab Dispos2008361812181818524871
   PubMed Web of Science ®Google Scholar
• WolffKStuetzAPimecrolimus for the treatment of inflammatory skin diseaseExpert Opin Pharmacother2004564365515013932
   PubMed Web of Science ®Google Scholar
• StarzlTETodoSFungJFK506 for liver, kidney and pancreas transplantationLancet19892100010042478846
   PubMed Web of Science ®Google Scholar
• US FDA Advisory Committee recommends approval for Tacrolimus ointmentSkin Ther Lett200065
   Google Scholar
• NakagawaHEtohTIshibashiYTacrolimus ointment for atopic dermatitisLancet19943448837522297
   PubMed Web of Science ®Google Scholar
• YamamotoTNishiokaKTopical tacrolimus: An effective therapy for facial psoriasisEur J Dermatol20031347147314693492
   PubMed Web of Science ®Google Scholar
• MancusoGBerdondiniRMTopical tacrolimus in the treatment of localized sclerodermaEur J Dermatol20031359059214721783
   PubMed Web of Science ®Google Scholar
• EvansAVPalmerRAHawkJKErythrodermic chronic actinic dermatitis responding only to topical tacrolimusPhotodermatol Photoimmunol Photomed200420596114738535
   PubMed Web of Science ®Google Scholar
• PeteringHKiehlPBreuerCKappAWerfelTPyoderma gangrenosum: Successful topical therapy with tacrolimus (FK506)Hautarzt200152475011220239
   PubMed Web of Science ®Google Scholar
• SakaneTMochizukiMInubaGMasudaKA phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet’s disease and allied conditionsRyumachi1995358028138594659
   PubMedGoogle Scholar
• VolzTCaroliULüdtkeHPimecrolimus cream 1% in erosive oral lichen planus – a prospective randomized double-blind vehicle-controlled studyBr J Dermatol200815993694118647310
   PubMed Web of Science ®Google Scholar
• SchuppeHRichter-HintzDStierleHEHomeyBRuzickaTLehmannPTopical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritisRheumatology20003910510610662882
   PubMed Web of Science ®Google Scholar
• GoldmanDTacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary reportJ Am Acad Dermatol20014499599811369912
   PubMed Web of Science ®Google Scholar
• GawrodgerDJOrmerodADShawLGuideline for the diagnosis and management of vitiligoBr J Dermatol20081591051107619036036
   PubMed Web of Science ®Google Scholar
• LampropoulosCED’CruzDPTopical tacrolimus treatment in a patient with dermatomyositisAnn Rheum Dis2005641376137716100347
   PubMed Web of Science ®Google Scholar
• RobertsonLNew and existing therapeutic options for hand eczemaSkin Therapy Lett2009141519585057
   PubMedGoogle Scholar
• WollinaUThe role of topical calcineurin inhibitors for skin diseases other than atopic dermatitisAm J Clin Dermatol2007815717317492844
   PubMed Web of Science ®Google Scholar
• LugerTPaulCPotential new indications of topical calcineurin inhibitorsDermatology2007215Suppl 1S45S54
   PubMed Web of Science ®Google Scholar
• CookBAWarshawEMRole of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: A review of pathophysiology, safety and efficacyAm J Clin Dermatol20091010311819222250
   PubMed Web of Science ®Google Scholar
• RallisEKorfitisCGregoriouSRigopoulosDAssigning new roles to topical tacrolimusExpert Opin Investig Drugs20071612671276
   PubMed Web of Science ®Google Scholar
• WolffDSteinerBHildebrandtGEdingerMHollerEPharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host diseaseCurr Pharm Res20091519741997
   PubMed Web of Science ®Google Scholar
• WooDKJamesWDTopical tacrolimus: A review of its uses in dermatologyDermatitis20051662115996345
   PubMed Web of Science ®Google Scholar
• DraelosZDUse of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areasCurr Med Res Opin20082498599418284804
   PubMed Web of Science ®Google Scholar
• GuptaAKChowMPimecrolimus: A reviewJ Eur Acad Dermatol Venereol20031749350312941081
   PubMed Web of Science ®Google Scholar
• LangleyRGLugerTACorkMJSchneiderDPaulCAn update on the safety and tolerability of pimecrolimus cream 1%: Evidence from clinical trials and post-marketing surveillanceDermatology2007215Suppl 1S27S44
   PubMedGoogle Scholar
• US Food and Drug AdministrationFDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointmentRockville, MDUS Food and Drug Administration2005
   Google Scholar
• LangelandTEnghVTopical use of tacrolimus and squamous cell carcinoma on the penisBr J Dermatol200515218318515656830
   PubMed Web of Science ®Google Scholar
• BeckerJCHoubenRVelterCSBröckerEBThe carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case reportBMC Cancer20066716405733
   PubMed Web of Science ®Google Scholar
• WooltortonEEczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): Cancer concernsCMAJ20051721179118015817641
   PubMed Web of Science ®Google Scholar
• NiwaYNasrIAre we starting to induce skin cancer in order to avoid topical steroidsJ Eur Acad Dermatol Venereol20051938738915857478
   PubMed Web of Science ®Google Scholar
• Gomez-LechonMJSerraltaADonatoMTThe immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytesBiochem Pharmacol2004682427243315548389
   PubMed Web of Science ®Google Scholar
• RustinMHThe safety of tacrolimus ointment for the treatment of atopic dermatitis: A reviewBr J Dermatol200715786187317854353
   PubMed Web of Science ®Google Scholar
• PaulCCorkMRossiABPappKABarbierNde ProstYSafety and tolerability of 1% pimecrolimus cream among infants: Experience with 1133 patients treated up to 2 yearsPediatrics2006117118128
   PubMed Web of Science ®Google Scholar
• RingJBarkerJBehrendtHReview of the potential photococarcinogenicity of topical calcineurin inhibitors: Position statement of the European Dermatology ForumJ Eur Acad Dermatol Venereol20051966367116268869
   PubMed Web of Science ®Google Scholar
• PappKAWerfelTFölster-HolstRLong-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year studyJ Am Acad Dermatol20055224024615692468
   PubMed Web of Science ®Google Scholar
• PappKABreuerKMeurerMLong-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationJ Am Acad Dermatol20055224725315692469
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationNovartis Elidel (pimecrolimus) cream 1% briefing documentRockville, MDUS Food and Drug Administration2005
   Google Scholar
• SchneeweissSDohertyMZhuSTopical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticosteroids and risk of lymphomaDermatology200921972119293564
   PubMed Web of Science ®Google Scholar
• ArellanoFMAranaAWentworthCEFernández-VidaurreCSchliengerRGCondeELymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United KingdomJ Allergy Clin Immunol20091231111111619361841
   PubMed Web of Science ®Google Scholar
• YoshimasuTOhtaniTSakamotoTOshimaAFurukawaFTopical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositisEur J Dermatol200212505211809595
   PubMed Web of Science ®Google Scholar
• WalkerSLKirbyBChalmersRJThe effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosusBr J Dermatol200214740540612174136
   PubMed Web of Science ®Google Scholar
• ZabawskiETreatment of cutaneous lupus with ElidelDermatol Online J200282512546779
   PubMedGoogle Scholar
• BacmanDTanbajewaAMegahedMRuzickaTKuhnATopical treatment with tacrolimus in lupus erythematosus tumidusHautarzt20035497797914513247
   PubMed Web of Science ®Google Scholar
• BöhmMGaubitzMLugerTAMetzeDBousmannGTopical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three casesDermatology200320738138514657631
   PubMed Web of Science ®Google Scholar
• KanekuraTYoshiiNTerasakiKMiyoshiHKanzakiTEfficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosusBr J Dermatol200314835335612588393
   PubMed Web of Science ®Google Scholar
• DrükeAGambichlerTAltmeyerPDreitagMKreuterA0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosusJ Dermatolog Treat200415636414754655
   PubMedGoogle Scholar
• De la Rosa CarrilloDChristensenOBTreatment of chronic discoid lupus erythematosus with topical tacrolimusActa Derm Venereol20048423323415202845
   PubMed Web of Science ®Google Scholar
• LampropoulosCESangleSHarrisonPHughesGRD’CruzDPTopical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: A possible alternativeRheumatology (Oxford)2004431383138515266063
   PubMed Web of Science ®Google Scholar
• KreuterAGambichlerTBreuckmannFPimecrolimus 1% cream for cutaneous lupus erythematosusJ Am Acad Dermatol20045140741015337984
   PubMed Web of Science ®Google Scholar
• Tlacuilo-ParraAGuevara-GutiérrezEGutiérrez-MurilloFPimecrolimus 1% cream for the treatment of discoid lupus erythematosusRheumatology (Oxford)2005441564156816159951
   PubMed Web of Science ®Google Scholar
• Jones-CaballeroMPẽnasPFGarcia-DiezABadiaXChrenMMThe Spanish version of skindex-29Int J Dermatol20003990791211168659
   PubMed Web of Science ®Google Scholar
• HeffernanMPNelsonMMSmithDIChungJH1% tacrolimus ointment in the treatment of discoid lupus erythematosusArch Dermatol20051411170117116172325
   PubMedGoogle Scholar
• MellerSBruch-GerharzDRuzickaTHomeyBTopical treatment of subacute-cutaneous lupus erythematosus with tacrolimusHautarzt20055636836915750673
   PubMed Web of Science ®Google Scholar
• CassisTBCallenJPBupropion-induced subacute cutaneous lupus erythematosusAustralas J Dermatol20054626626916197429
   PubMedGoogle Scholar
• SuganoMShintaniYKobayashiKSakakiburaNIsomuraIMoritaASuccessful treatment with topical tacrolimus in four cases of discoid lupus erythematosusJ Dermatol20063388789117169097
   PubMed Web of Science ®Google Scholar
• Von PelchrzimRSchmookTFriedrichMWormMEfficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosusInt J Dermatol200645848516426386
   PubMed Web of Science ®Google Scholar
• NagaoKChenKRA case of lupus erythematosus/lichen planus overlap syndromeJ Dermatol20063318719016620224
   PubMed Web of Science ®Google Scholar
• TzungTYLiuYSChangHWTacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: A randomized, double-blind, bilateral comparison studyBr J Dermatol200715619119217199600
   PubMed Web of Science ®Google Scholar
• MadanVAugustPJChalmersRJEfficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: A cohort studyClin Exp Dermatol20093470570819077095
   PubMedGoogle Scholar
• WiniskiAWangSSchwendingerBStuetzAInhibition of T-cell activation in vitro in human peripheral blood mononuclear cell by pimecrolimus and glucocorticosteroids and combinations thereofExp Dermatol20071669970417620098
   PubMed Web of Science ®Google Scholar
• EllisCNDrakeLAPrendergastMMCost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitisJ Am Acad Dermatol20034855356312664019
   PubMed Web of Science ®Google Scholar
• WollinaUHanselGThe use of topical calcineurin inhibitors in lupus erythematosus: An overviewJ Eur Acad Dermatol Venereol2008221618005117
   PubMed Web of Science ®Google Scholar
• BernatskySRamsey-GoldmanRIsenbergDHodgkin’s lymphoma in systemic lupus erythematosusRheumatology (Oxford)20074683083217255135
   PubMed Web of Science ®Google Scholar